Biocytogen is a global biotech company that drives the research and development of new drugs with innovative technologies.
Using RenMabTM and RenLiteTM mice for fully human antibody production, Biocytogen has integrated its monoclonal and bispecific antibody development platforms, in vivo drug efficacy screening platforms and strong clinical development ability to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody in collaboration with global partners for more than 1000 druggable targets, known as the RenMiceTM HiTS Platform.
We are looking forward to see your active participation in the network!
You can find here more information about Biocytogen.